Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | The role of DLI & molecular monitoring in patients with myelofibrosis who relapse after SCT

Nico Gagelmann • 20 Oct 2023
COSTEM 2023
Myelofibrosis Myeloproliferative Neoplasms

In this video, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the importance of molecular monitoring when treating patients with myelofibrosis (MF) who relapse after stem cell transplantation (SCT), and further highlights the value of donor lymphocyte infusion (DLI) in this patient population. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nico Gagelmann

0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024
1:22
The role of splenic irradiation in transplant for patients with myelofibrosis
Nico Gagelmann • 15 Feb 2024
1:41
Predicting outcomes in patients with R/R MM undergoing CAR T-cell therapy: the MyCARe model
Nico Gagelmann • 15 Feb 2024
2:03
Looking to the future in the field of transplantation
Nico Gagelmann • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals